InVitae Corp (NASDAQ:NVTA) Releases Earnings Results, Misses Estimates By $0.02 EPS

InVitae Corp (NASDAQ:NVTA) posted its quarterly earnings results on Monday, August 7th. The medical research company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by $0.02, Briefing.com reports. InVitae Corp had a negative net margin of 199.20% and a negative return on equity of 153.27%. The company had revenue of $14.34 million for the quarter, compared to the consensus estimate of $13.31 million. During the same period in the prior year, the firm posted ($0.77) EPS. The business’s revenue was up 157.0% on a year-over-year basis.

InVitae Corp (NVTA) traded up 0.52% during trading on Friday, reaching $9.60. 235,304 shares of the company’s stock traded hands. InVitae Corp has a 12-month low of $5.76 and a 12-month high of $11.88. The company has a 50 day moving average price of $9.56 and a 200-day moving average price of $9.83. The company’s market cap is $418.02 million.

NVTA has been the subject of several research analyst reports. ValuEngine raised shares of InVitae Corp from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. BidaskClub raised shares of InVitae Corp from a “sell” rating to a “hold” rating in a research note on Thursday, August 3rd. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $15.00 price target (up previously from $14.00) on shares of InVitae Corp in a research note on Wednesday, August 9th. Finally, Zacks Investment Research raised shares of InVitae Corp from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $12.94.

Large investors have recently made changes to their positions in the stock. Donald L. Hagan LLC purchased a new stake in shares of InVitae Corp during the first quarter worth approximately $111,000. Renaissance Technologies LLC bought a new position in InVitae Corp during the fourth quarter worth approximately $879,000. HighTower Advisors LLC increased its position in InVitae Corp by 11.9% in the first quarter. HighTower Advisors LLC now owns 252,744 shares of the medical research company’s stock worth $2,792,000 after buying an additional 26,787 shares during the period. State Street Corp increased its position in InVitae Corp by 9.4% in the fourth quarter. State Street Corp now owns 338,514 shares of the medical research company’s stock worth $2,688,000 after buying an additional 29,017 shares during the period. Finally, Highbridge Capital Management LLC bought a new position in InVitae Corp during the first quarter worth approximately $302,000.

WARNING: This piece was first published by BNB Daily and is the property of of BNB Daily. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/invitae-corp-nasdaqnvta-releases-quarterly-earnings-results-misses-estimates-by-0-02-eps-updated.html.

About InVitae Corp

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Earnings History for InVitae Corp (NASDAQ:NVTA)

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply